Insider sales are routine and immaterial relative to market cap. No bearish signal. Monitor next earnings (likely late July) for any guidance changes, but this cluster does not indicate informed selling.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 3 $164.23entry
- T+1 · 6mo ago +1.58%α +1.18% · $166.83
- T+5 · 5mo ago −2.05%α +1.77% · $160.86
- T+20 · 5mo ago +2.16%α +3.28% · $167.77
- T+60 · 3mo ago −5.36%α −7.59% · $155.43
Price Chart
How similar events traded
Executive Summary
Three Neurocrine executives (CSO, Chief Corp. Affairs Officer, Chief Regulatory Officer) sold a total of $2.73M in open-market shares over a 5-day window. The sales are tied to option exercises and are small relative to the $16.2B market cap (~0.017%), making them routine portfolio diversification rather than a bearish signal. Director grants on May 27 are non-cash and carry no economic signal.
Key Financial Metrics
Key Facts
- Total open-market sales: $2.73M across 3 insiders (CSO, Chief Corp. Affairs Officer, Chief Regulatory Officer)
- Sales represent ~0.017% of NBIX's $16.2B market cap, well below the 0.1% materiality threshold
- CSO Onyia Jude sold 22,000 shares for $3.47M total across two days, all tied to option exercises at $84.74/share
- Chief Regulatory Officer Delaet Ingrid sold 2,261 shares for $354K, also tied to option exercises
- Seven directors received non-cash stock grants on May 27, no economic signal
- No 10b5-1 plan disclosure in the filing, but the pattern (option exercise + immediate sale) is standard for tax coverage
Financial Impact
Total insider sales of $2.73M, or 0.017% of market cap, immaterial
Risk Factors
- No material risk identified from this insider activity alone
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1780438125207 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers